The use of first-line immunotherapy combination with Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) continues to show robust, long-term benefit in patients with microsatellite instability high (MSI-H) or with mismatch repair-deficient (dMMR) metastatic (spreading) colorectal cancer, according to new study results presented at the 2020 ASCO annual meeting.
Treatment with the targeted drug Tagrisso (osimertinib) as an adjuvant therapy (used in addition to primary therapy, such as surgery or chemotherapy) significantly reduces disease recurrence in patients with localized non–small-cell lung cancer (NSCLC) and an EGFR gene mutation (alteration).
A total of 80% of patients with relapsed (coming back) or refractory (not responding to therapy) slow-growing (indolent) non-Hodgkin lymphoma (NHL)—including patients with follicular lymphoma or marginal-zone lymphoma (MZL)—achieved a complete response (no sign of cancer) to Yescarta (axicabtagene ciloleucel), an anti-CD19 CAR T-cell therapy.
Several immunotherapies known as immune checkpoint inhibitors are available today for patients with melanoma, as well as targeted therapies for patients with a BRAF or MEK gene mutation, but there are no effective treatments approved for patients with metastatic (spreading) or nonresectable (cannot be removed by surgery) melanoma whose disease progressed (got worse) after using an immune checkpoint inhibitor, or a BRAF or MEK inhibitor for those with gene mutations.
The follow-up results of more than 5 years of the multicenter phase 3 SOLO2 clinical trial of women with ovarian cancer were presented at the 2020 ASCO annual meeting, showing improved survival with the use of Lynparza (olaparib) compared with placebo.
Genetic testing, genomic testing, molecular profiling—how can you make sense of these terms to ensure you receive the best test and best treatment in this era of targeted therapies? A group of experts and patient advocates provide answers to these questions.
New treatments are becoming available for patients with cholangiocarcinoma (bile duct cancer). Testing for specific biomarkers is crucial to ensure each patient receives the best available treatment for any associated biomarker.